Research programme: androgen receptor antagonists - Janssen Research & DevelopmentAlternative Names: SARD programme - Aragon Pharmaceuticals
Latest Information Update: 28 Aug 2013
At a glance
- Originator University of California System
- Developer Janssen Research & Development
- Class Small molecules
- Mechanism of Action Androgen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Prostate cancer